Introduction: The role of some cytokines, such as interleukin (IL) and tumor necrosis factor-α (TNF-α), in serum in community-acquired pneumonia (CAP) has been mentioned. There are few results on changes in serum cytokines in patients with bacterial CAP. This study aimed at the relationship...
Introduction: Despite the theoretical importance of serum immunoglobulin (Ig) in the outcome of COPD exacerbations, the existing evidence for this has not been enough. This study was performed to evaluate changes in serum Ig levels and their relationship with outcomes of acute infectious exacerbations in patients with COPD. Methods: The prospective study was conducted at Military Hospital 103 from August 2017 to April 2019. Group D patients with COPD with infectious exacerbation were selected for participation in the study. The control group consisted of 30 healthy people. The patients were provided clinical examination and laboratory service; simultaneously, we measured their serum Ig levels (total IgG, IgG1, IgG2, IgG3, IgG4) at two time points: at admission (T1) and the final health outcome (T2). Results: The median levels of total IgG in patients at times T1 and T2 were significantly lower compared with those in the healthy group (1119.3 mg/dL and 1150.6 mg/dL compared with 2032.2 mg/dL) (p < 0.001). Regarding changes among IgG subclasses, the IgG1, IgG3, and IgG4 levels measured at T1 and T2 were reduced significantly compared with the control group (p < 0.05); the IgG3 levels at T1 were significantly higher than those at T2. IgG3 levels in patients with life-threatening exacerbations were significantly lower than the remaining ones (24.6 (26.8–155.5) mg/dL and 25.6 (29.5–161.2) mg/dL, respectively, p = 0.023). Conclusions: In group D patients with COPD with infectious exacerbations, there was a decrease in the serum IgG, IgG1, IgG3, and IgG4 levels. IgG3 levels were associated with the severity of COPD exacerbation.
(1) Background: Asthma exacerbations represent significant clinical events, however, the underlying inflammatory mechanisms and cytokine profiles in patients with frequent exacerbations remain incompletely understood; (2) Methods: In this prospective, cross-sectional study of 120 stable asthma patients, we compared the serum concentrations of eight key cytokines (IL-4, IL-12, IL-13, IL-17, IFN-α, IFN-γ, TNF-α, and IL-1β) between two groups: 60 patients with frequent exacerbations (≥ 2 events per year) and 60 matched controls with few exacerbations (1 event per year); (3) Results: Patients with frequent exacerbations showed significantly higher serum concentrations of IL-4 and IL-13 (p < 0.05), along with an increased prevalence of allergic history and comorbidities (chronic rhinosinusitis, GERD, OSA; all p < 0.05). The IgE levels correlated positively with IFN-α (rh = 0.26) and TNF-α (rh = 0.29), while the FeNO levels correlated with IL-17 (rh = 0.26) and IL-1β (rh = 0.33) (all p < 0.05); (4) Conclusions: Our findings identify a distinct cytokine signature in frequent exacerbators characterized by elevated IL-4 and IL-13 levels. The correlations between specific cytokines and established biomarkers suggest potential mechanisms underlying exacerbation susceptibility, which may inform targeted therapeutic strategies for this high-risk population.
English: Objective: This study aimed to compare clinical characteristics and plasma cytokine profiles among patients with asthma, asthma combined with smoking history, asthma with fixed airflow obstruction (FAO) and asthma–COPD overlap (ACO), to identify distinct inflammatory signatures. Methods: A prospective, cross-sectional study was conducted involving 120 clinically stable asthma patients stratified into four groups: asthma (n = 56), asthma + smoking (n = 15), asthma + FAO (n = 34) and ACO (n = 15). Clinical assessments, spirometry and multiplex cytokine analysis were performed to evaluate inflammatory and functional parameters. Results: Significant elevations in IL-1β, IL-17 and tumour necrosis factor alpha (TNF-α) were observed in the ACO group compared to asthma and asthma + FAO cohorts (P < 0.01). Specifically, IL-1β levels in ACO reached 3.8 ng/L [2.7–4.8], nearly threefold higher than in asthma (1.4 ng/L) and asthma + FAO (1.0 ng/L). IL-17 and TNF-α concentrations were similarly elevated in ACO (16.4 ng/L and 18.8 ng/L, respectively). No significant differences were found in IFN-α, IFN-γ, IL-4, IL-12 or IL-13. Conclusion: ACO exhibits distinct immunopathological characteristics, notably elevated concentrations of IL-1β, IL-17 and TNF-α relative to asthma and asthma + FAO cohorts. The combined use of spirometric indices and biomarker profiling may enhance phenotypic stratification and inform the development of targeted biologic therapies for obstructive airway diseases.
30 January 2023 in VietNam Military Medical Unisversity
Objectives: To evaluate membrane and soluble PD-L1 expression in advanced-stage non-small cell lung cancer (NSCLC) patients. Subjects and methods: A prospective, cross-sectional study on 50 advanced-stage NSCLC patients treated at the Respiratory Center, Military Hospital 103 from January to September 2019; the control group consists of 30 normal people who had personal periodic health examination at the Outpatient Department, Military Hospital 103. Membrane PD-L1 (mPD-L1) expression assay was carried out applying immunohistochemistry on cancer tissue samples, using PD-L1 73 - 10 antibody. The serum level of soluble PD-L1 (sPD-L1) was measured using the ELISA technique. Results: 62% of lung cancer tissue samples were positive for mPD-L1 (TPS ³ 1%), of which 51.6% were highly positive and 48.4% low positive. The concentration of sPD-L1 in NSCLC group was significantly higher than that of the control group (2.11 ± 1.48 and 0.73 ± 0.57 ng/mL; p < 0.001). sPD-L1 concentration in the mPD-L1 negative group (1.61 ± 1.37 ng/mL) was statistically significantly lower than that in the mPD-L1 positive group (2.42 ± 1.49 ng/mL) (p = 0.03). At the cut-off value of 1.815 ng/mL, sPD-L1 had a diagnostic value for mPD-L1 positive with a sensitivity of 65% and specificity of 68%, area under the curve was 0.678 (95% CI: 0.521 - 0.835; p = 0.036). Conclusion: The rate of mPD-L1 positive expression in NSCLC tissue was 62%. The concentration of sPD-L1 in NSCLC patients was significantly higher than that in the control group. No significant relationship was found between the two forms of PD-L1 expression.
(1) Background: Asthma exacerbations represent significant clinical events, yet the underlying inflammatory mechanisms and cytokine profiles in patients with frequent exacerbations remain incompletely understood; (2) Methods: In this prospective, cross-sectional study of 120 stable asthma patients, we compared serum concentrations of eight key cytokines (IL-4, IL-12, IL-13, IL-17, IFN-α, IFN-γ, TNF-α, and IL-1β) between two groups: 60 patients with frequent exacerbations (≥2/year) and 60 matched controls with few exacerbations (1/year); (3) Results: Patients with frequent exacerbations showed significantly higher serum concentrations of IL-4 and IL-13 (p < 0.05), along with increased prevalence of allergic history and comorbidities (chronic rhinosinusitis, GERD, OSA; all p < 0.05). IgE levels correlated positively with IFN-α (rh = 0.26) and TNF-α (rh = 0.29), while FeNO levels correlated with IL-17 (rh = 0.26) and IL-1β (rh = 0.33) (all p < 0.05); (4) Conclusions: Our findings identify a distinct cytokine signature in frequent exacerbators characterized by elevated IL-4 and IL-13 levels. The correlations between specific cytokines and established biomarkers suggest potential mechanisms underlying exacerbation susceptibility, which may inform targeted therapeutic strategies for this high-risk population.